ARTICLE | Company News
BioAtla, BioMotiv deal
February 24, 2014 8:00 AM UTC
BioAtla granted BioMotiv exclusive, worldwide rights to develop and commercialize an IL-22 mAb to treat inflammatory bowel disease (IBD) and cancer. BioMotiv launched newco Kodosil Bio LLC to develop ...